Last reviewed · How we verify
Chlorhexidine 0.2%, Curasept
Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, providing antiseptic and disinfectant effects.
Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, providing antiseptic and disinfectant effects. Used for Oral antisepsis and plaque control, Prevention of gingivitis and periodontal disease, Oral rinse for antimicrobial purposes.
At a glance
| Generic name | Chlorhexidine 0.2%, Curasept |
|---|---|
| Sponsor | University of Oslo |
| Drug class | Antimicrobial agent / Antiseptic |
| Modality | Small molecule |
| Therapeutic area | Oral Health / Dentistry |
| Phase | FDA-approved |
Mechanism of action
Chlorhexidine works by binding to and disrupting the integrity of bacterial cell membranes, leading to leakage of cellular contents and cell death. It also denatures bacterial proteins and interferes with metabolic processes. At the 0.2% concentration in Curasept, it is effective against a wide range of gram-positive and gram-negative bacteria, making it suitable for oral antisepsis and plaque control.
Approved indications
- Oral antisepsis and plaque control
- Prevention of gingivitis and periodontal disease
- Oral rinse for antimicrobial purposes
Common side effects
- Tooth staining (brown discoloration)
- Taste alteration
- Oral irritation or burning sensation
- Increased calculus formation
Key clinical trials
- Investigating the Effect of Chlorine Dioxide and Chlorhexidine Mouthwash on Bad Breath (NA)
- Clinical Effect of Chlorhexidine Mouthwash After Periodontal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorhexidine 0.2%, Curasept CI brief — competitive landscape report
- Chlorhexidine 0.2%, Curasept updates RSS · CI watch RSS
- University of Oslo portfolio CI